on April 8, 2004
Published online before print April 8, 2004, doi: 10.1161/01.STR.0000126822.01756.99
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on October 23, 2003
From Human Genetics Division (A.R.M., B.Z., S.Y.), Department of Pathology (P.J.G.), Institute of Human Nutrition (P.C.C., R.F.G.), School of Medicine, University of Southampton, UK; Department of Vascular Surgery (K.R., G.E.M., C.P.S.), Southampton General Hospital, UK; Atherosclerosis Research Unit (P.E.), Karolinska Hospital, Sweden; Molecular Pharmacology (W.L.M.), AstraZeneca, Mölndal, Sweden; Department of Surgery (K.R.), Faculty of Medicine, Chiang Mai University, Thailand. * To whom correspondence should be addressed. E-mail: Shu.Ye{at}soton.ac.uk.
Background and Purpose--Previous studies have shown that atherosclerotic lesions express a number of matrix metalloproteinases (MMPs). Here we investigated whether transcript levels of MMP-1, -3, -7, -9, and -12 in carotid atherosclerotic plaques were correlated with histological features and clinical manifestations. Methods--Atherosclerotic plaques (n=50) removed from patients undergoing carotid endarterectomy were classified histologically using a system proposed by Virmani et al, and MMP-1, -3, -7, -9, and -12 transcript levels in these tissues were quantified by real-time reverse-transcriptase polymerase chain reaction. Results--Compared to plaques with a thick fibrous cap, those with a thin cap had a 7.8-fold higher MMP-1 transcript level (P=0.006). MMP-3, -7, and -12 were 1.5-fold, 1.8-fold, and 2.1-fold, respectively, higher in thin cap plaques, but the differences did not reach statistical significance. MMP-12 transcript levels were significantly increased in ruptured plaques compared with lesions without cap disruption (P=0.001). MMP-9 transcript levels were similar among the different types of lesion. MMP-1 and -12 transcript levels were significantly higher in plaques from patients with amaurosis fugax, than in those from asymptomatic patients (P=0.029 and P=0.008 for MMP-1 and MMP-12, respectively), than in those from patients with stroke (P=0.027 and P=0.001, respectively), and than in those from patients with transient ischemic attack (P=0.046 and P=0.008, respectively). Conclusions--These data support a role of MMP-1 and -12 in determining atherosclerotic plaque stability.
Revised on January 20, 2004
Accepted on February 13, 2004
Differences in Matrix Metalloproteinase-1 and Matrix Metalloproteinase-12 Transcript Levels Among Carotid Atherosclerotic Plaques with Different Histopathological Characteristics
Angharad R. Morgan BSc;
Key words: carotid arteries • atherosclerosis • metalloproteinases • gene expression
This article has been cited by other articles:
 |
|
 |
|
  Y.-C. Cheng, W.-H. L. Kao, B. D. Mitchell, J. R. O'Connell, H. Shen, P. F. McArdle, Q. Gibson, K. A. Ryan, A. R. Shuldiner, and T. I. Pollin Genome-Wide Association Scan Identifies Variants near Matrix Metalloproteinase (MMP) Genes on Chromosome 11q21-22 Strongly Associated With Serum MMP-1 Levels Circ Cardiovasc Genet, August 1, 2009; 2(4): 329 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-W. Wu, H.-L. Kao, M.-F. Chen, B.-C. Lee, W.-Y. I. Tseng, J.-S. Jeng, K.-Y. Tzen, R.-F. Yen, P.-J. Huang, and W.-S. Yang Characterization of Plaques Using 18F-FDG PET/CT in Patients with Carotid Atherosclerosis and Correlation with Matrix Metalloproteinase-1 J. Nucl. Med., February 1, 2007; 48(2): 227 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Abilleira, S. Bevan, and H. S Markus The role of genetic variants of matrix metalloproteinases in coronary and carotid atherosclerosis J. Med. Genet., December 1, 2006; 43(12): 897 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Leger, L. Covic, and A. Kuliopulos Protease-Activated Receptors in Cardiovascular Diseases Circulation, September 5, 2006; 114(10): 1070 - 1077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Devel, V. Rogakos, A. David, A. Makaritis, F. Beau, P. Cuniasse, A. Yiotakis, and V. Dive Development of Selective Inhibitors and Substrate of Matrix Metalloproteinase-12 J. Biol. Chem., April 21, 2006; 281(16): 11152 - 11160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Nighoghossian, L. Derex, and P. Douek The Vulnerable Carotid Artery Plaque: Current Imaging Methods and New Perspectives Stroke, December 1, 2005; 36(12): 2764 - 2772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Pearce, D.-A. Tregouet, A. Samnegard, A. R. Morgan, C. Cox, A. Hamsten, P. Eriksson, and S. Ye Haplotype Effect of the Matrix Metalloproteinase-1 Gene on Risk of Myocardial Infarction Circ. Res., November 11, 2005; 97(10): 1070 - 1076. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kazi, C. Zhu, J. Roy, G. Paulsson-Berne, A. Hamsten, J. Swedenborg, U. Hedin, and P. Eriksson Difference in Matrix-Degrading Protease Expression and Activity Between Thrombus-Free and Thrombus-Covered Wall of Abdominal Aortic Aneurysm Arterioscler Thromb Vasc Biol, July 1, 2005; 25(7): 1341 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kyriakou, C. Hodgkinson, D. E. Pontefract, S. Iyengar, W. M. Howell, Y.-k. Wong, P. Eriksson, and S. Ye Genotypic Effect of the -565C>T Polymorphism in the ABCA1 Gene Promoter on ABCA1 Expression and Severity of Atherosclerosis Arterioscler Thromb Vasc Biol, February 1, 2005; 25(2): 418 - 423. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tayebjee, G. Y.H. Lip, and R. J. MacFadyen The Unifying Role of Matrix Metalloproteinases in Atheroma and Vascular Stroke Stroke, October 1, 2004; 35(10): 2239 - 2239. [Full Text] [PDF]
|
|